270 related articles for article (PubMed ID: 22133902)
21. Structural basis for inhibition of protein tyrosine phosphatases by Keggin compounds phosphomolybdate and phosphotungstate.
Heo YS; Ryu JM; Park SM; Park JH; Lee HC; Hwang KY; Kim J
Exp Mol Med; 2002 Jul; 34(3):211-23. PubMed ID: 12216113
[TBL] [Abstract][Full Text] [Related]
22. Protein tyrosine phosphatases: prospects for therapeutics.
Zhang ZY
Curr Opin Chem Biol; 2001 Aug; 5(4):416-23. PubMed ID: 11470605
[TBL] [Abstract][Full Text] [Related]
23. Structure-based design of selective and potent inhibitors of protein-tyrosine phosphatase beta.
Lund IK; Andersen HS; Iversen LF; Olsen OH; Møller KB; Pedersen AK; Ge Y; Holsworth DD; Newman MJ; Axe FU; Møller NP
J Biol Chem; 2004 Jun; 279(23):24226-35. PubMed ID: 15024017
[TBL] [Abstract][Full Text] [Related]
24. Targeting protein tyrosine phosphatases for anticancer drug discovery.
Scott LM; Lawrence HR; Sebti SM; Lawrence NJ; Wu J
Curr Pharm Des; 2010 Jun; 16(16):1843-62. PubMed ID: 20337577
[TBL] [Abstract][Full Text] [Related]
25. Steric hindrance as a basis for structure-based design of selective inhibitors of protein-tyrosine phosphatases.
Iversen LF; Andersen HS; Møller KB; Olsen OH; Peters GH; Branner S; Mortensen SB; Hansen TK; Lau J; Ge Y; Holsworth DD; Newman MJ; Hundahl Møller NP
Biochemistry; 2001 Dec; 40(49):14812-20. PubMed ID: 11732900
[TBL] [Abstract][Full Text] [Related]
26. Bidentate inhibitors of protein tyrosine phosphatases.
Low JL; Chai CL; Yao SQ
Antioxid Redox Signal; 2014 May; 20(14):2225-50. PubMed ID: 24206395
[TBL] [Abstract][Full Text] [Related]
27. Protein tyrosine phosphatases: strategies for distinguishing proteins in a family containing multiple drug targets and anti-targets.
Hoffman BT; Nelson MR; Burdick K; Baxter SM
Curr Pharm Des; 2004; 10(10):1161-81. PubMed ID: 15078147
[TBL] [Abstract][Full Text] [Related]
28. Chemical and mechanistic approaches to the study of protein tyrosine phosphatases.
Zhang ZY
Acc Chem Res; 2003 Jun; 36(6):385-92. PubMed ID: 12809524
[TBL] [Abstract][Full Text] [Related]
29. Knowledge-based characterization of similarity relationships in the human protein-tyrosine phosphatase family for rational inhibitor design.
Vidović D; Schürer SC
J Med Chem; 2009 Nov; 52(21):6649-59. PubMed ID: 19810703
[TBL] [Abstract][Full Text] [Related]
30. Suramin derivatives as inhibitors and activators of protein-tyrosine phosphatases.
McCain DF; Wu L; Nickel P; Kassack MU; Kreimeyer A; Gagliardi A; Collins DC; Zhang ZY
J Biol Chem; 2004 Apr; 279(15):14713-25. PubMed ID: 14734566
[TBL] [Abstract][Full Text] [Related]
31. A combinatorial strategy for the acquisition of potent and specific protein tyrosine phosphatase inhibitors.
Zhang S; Chen L; Lawrence DS; Zhang ZY
Methods Mol Biol; 2012; 928():53-65. PubMed ID: 22956133
[TBL] [Abstract][Full Text] [Related]
32. Protein-tyrosine phosphatases: structure, mechanism, and inhibitor discovery.
Burke TR; Zhang ZY
Biopolymers; 1998; 47(3):225-41. PubMed ID: 9817026
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of lymphoid tyrosine phosphatase by benzofuran salicylic acids.
Vang T; Xie Y; Liu WH; Vidović D; Liu Y; Wu S; Smith DH; Rinderspacher A; Chung C; Gong G; Mustelin T; Landry DW; Rickert RC; Schürer SC; Deng SX; Tautz L
J Med Chem; 2011 Jan; 54(2):562-71. PubMed ID: 21190368
[TBL] [Abstract][Full Text] [Related]
34. Discovery and SAR of a novel selective and orally bioavailable nonpeptide classical competitive inhibitor class of protein-tyrosine phosphatase 1B.
Andersen HS; Olsen OH; Iversen LF; Sørensen AL; Mortensen SB; Christensen MS; Branner S; Hansen TK; Lau JF; Jeppesen L; Moran EJ; Su J; Bakir F; Judge L; Shahbaz M; Collins T; Vo T; Newman MJ; Ripka WC; Møller NP
J Med Chem; 2002 Sep; 45(20):4443-59. PubMed ID: 12238924
[TBL] [Abstract][Full Text] [Related]
35. Inhibitors of protein tyrosine phosphatases: next-generation drugs?
Bialy L; Waldmann H
Angew Chem Int Ed Engl; 2005 Jun; 44(25):3814-39. PubMed ID: 15900534
[TBL] [Abstract][Full Text] [Related]
36. Targeting PTPs with small molecule inhibitors in cancer treatment.
Jiang ZX; Zhang ZY
Cancer Metastasis Rev; 2008 Jun; 27(2):263-72. PubMed ID: 18259840
[TBL] [Abstract][Full Text] [Related]
37. Targeting protein tyrosine phosphatase to unravel possible inhibitors for Streptococcus pneumoniae using molecular docking, molecular dynamics simulations coupled with free energy calculations.
Zaman Z; Khan S; Nouroz F; Farooq U; Urooj A
Life Sci; 2021 Jan; 264():118621. PubMed ID: 33164832
[TBL] [Abstract][Full Text] [Related]
38. Rational design of allosteric-inhibition sites in classical protein tyrosine phosphatases.
Chio CM; Yu X; Bishop AC
Bioorg Med Chem; 2015 Jun; 23(12):2828-38. PubMed ID: 25828055
[TBL] [Abstract][Full Text] [Related]
39. Integrating virtual and biochemical screening for protein tyrosine phosphatase inhibitor discovery.
Martin KR; Narang P; Medina-Franco JL; Meurice N; MacKeigan JP
Methods; 2014 Jan; 65(2):219-28. PubMed ID: 23969317
[TBL] [Abstract][Full Text] [Related]
40. Targeting Tyrosine Phosphatases: Time to End the Stigma.
Stanford SM; Bottini N
Trends Pharmacol Sci; 2017 Jun; 38(6):524-540. PubMed ID: 28412041
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
